Autoimmune thyroid disease in children and adolescents with idiopathic pulmonary arterial hypertension

Circulation Journal

Volumn 74, Issue 2, 2010, Pages 371-374

  Satoh, Mari ^a   Aso, Keiko ^a   Nakayama, Tomotaka ^a   Naoi, Kazuyuki ^a   Ikehara, Satoshi ^a   Uchino, Yumiko ^a   Shimada, Hiromitsu ^a   Takatsuki, Shinichi ^a   Matsuura, Hiroyuki ^a   Saji, Tsutomu ^a  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

Bone morphogenetic protein receptor II; Graves' disease; Idiopathic pulmonary arterial hypertension; Silent thyroiditis

Indexed keywords

ANTITHYROID AGENT; BERAPROST; BOSENTAN; MECHIMAZOLE; PROSTACYCLIN; SILDENAFIL; THYROID ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EUTHYROIDISM; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; IDIOPATHIC DISEASE; MALE; PREVALENCE; PULMONARY HYPERTENSION; THYROID DISEASE; THYROID FUNCTION TEST; THYROIDITIS;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CHILD; CHILD, PRESCHOOL; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; HYPERTHYROIDISM; JAPAN; MALE; PREVALENCE; RETROSPECTIVE STUDIES; THYROID FUNCTION TESTS; TIME FACTORS;

EID: 75749101036     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0369     Document Type: Article

References (34)

1. Simonneau G, Galié N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S - 12S.
2. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic receptor-II gene. Am J Hum Genet 2000; 67: 737 - 744.
3. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Philips III JA, Loyd JE, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension: The International PPH Consortium. Nat Genet 2000; 26: 81 - 84.
4. Trembath RC, Thomson JR, Machado RD, Morgan NV, Aktinson C, Winship I, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 325 - 334.
5. Morrell NW. Pulmonary hypertension due to BMPR2 mutation: A new paradigm for tissue remodeling? Proc Am Thorac Soc 2006; 3: 680 - 686.
6. Newman JH, Phillips III JA, Loyd JE. The enigma of pulmonary arterial hypertension: New insights from genetic studies. Ann Intern Med 2008; 148: 278 - 283.
7. Nakayama T, Shimada H, Takatsuki S, Hoshida H, Ishikita T, Matsuura H, et al. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children. Circ J 2007; 71: 1785 - 1790.
8. Akagi S, Matsubara H, Miyaji K, Ikeda E, Dan K, Tokunaga N, et al. Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. Circ J 2008; 72: 1142 - 1146.
9. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066 - 2069.
10. Badesch DB, Wynne KM, Bonvallet S, Voelkel NF, Ridgway C, Groves BM. Hypothyroidism and primary pulmonary hypertension: An autoimmune pathogenetic link? Ann Intern Med 1993; 119: 44 - 46.
11. Yanai-Landau H, Amital H, Bar-Dayan Y, Levy Y, Gur H, Lin HC, et al. Autoimmune aspects of primary pulmonary hypertension. Pathobiology 1995; 63: 71 - 75.
12. Curnock AL, Dweik RA, Higgins BH, Saadi HF, Arroliga AC. High prevalence of hypothyroidism in patients with primary pulmonary hypertension. Am J Med Sci 1999; 318: 289 - 292.
13. Ferris A, Jacobs T, Widlitz A, Barst RJ, Morse JH. Pulmonary arterial hypertension and thyroid disease [Letter]. Chest 2001; 119: 1980 - 1981.
14. Chu JW, Kao PN, Faul JL, Doyle RL. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002; 122: 1668 - 1673.
15. Wawrzyńska L, Kurzyna M, Kuca P, Fijałkowska A, Kober J, Florczyk M, et al. Autoimmune thyroid diseases in patients with primary pulmonary hypertension. Pneumonol Alergol Pol 2004; 72: 19 - 22.
16. Li JH, Safford RE, Aduen JF, Heckman MG, Crook JE, Burger CD. Pulmonary hypertension and thyroid disease. Chest 2007; 132: 793 - 797.
17. Castillo Palma MJ, García Hernández FJ, Montero Benavides P, González León R, Ocaña Medina C, Sánchez Román J. Thyroid dysfunction inpatients with pulmonary arterial hypertension: A cohort study of 58 patients. Med Clin (Barc) 2009; 132: 695 - 700.
18. Fujiwara M, Yagi H, Matsuoka R, Akimoto K, Furutani M, Imamura S, et al. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. Circ J 2008; 72: 127 - 133.
19. Okamura K, Ueda K, Sone H, Ikenoue H, Hasuo Y, Sato K, et al. A sensitive thyroid hormone assays for screening of thyroid functional disorder in elderly Japanese. J Am Geriatr Soc 1989; 37: 317 - 322.
20. Konno N, Yuri K, Taguchi H, Miura K, Taguchi S, Hagiwara K, et al. Screening for thyroid diseases in an iodine sufficient area with sensitive thyrotrophin assays, and serum thyroid autoantibody and urinary iodide determinations. Clin Endocrinol (Oxf) 1993; 38: 273 - 281.
21. Kasai K, Hiraiwa M, Suzuki Y, Banba N, Emoto T, Nakamura T, et al. Prostacyclin stimulation of adenylate cyclase activity in human thyroid membranes. Horm Metab Res 1986; 18: 625 - 629.
22. Chadha C, Pritzker M, Mariash CN. Effect of epoprostenol on the thyroid gland: Enlargement and secretion of thyroid hormone. Endocr Pract 2009; 15: 116 - 121.
23. Korniszewski L, Kurzyna M, Stolarski B, Torbicki A, Smerdel A, Ploski R. Fatal primary hypertension in a 30-yr-old female with APECED syndrome. Eur Respir J 2003; 22: 709 - 711.
24. Bertino G, Ardiri AM, Boemi PM, Ierna D, Pulvirenti D, Neri S. A case of overlap syndrome: Autoimmune idiopathic hepatitis/pulmonary idiopathic hypertension. Clin Ter 2007; 158: 313 - 315.
25. Nicolls MR, Teraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF. Autoimmunity and pulmonary hypertension: A perspective. Eur Respir J 2005; 26: 1110 - 1118.
26. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000; 37: 741 - 745.
27. Urist MR, Delange RJ, Finerman GA. Bone cell differentiation and growth factors. Science 1983; 220: 680 - 686.
28. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: Transcriptional targets, regulation of signals and signaling crosstalk. Cytokine Growth Factor Rev 2005; 16: 261 - 263.
29. Suzuki J, Otsuka F, Inagaki K, Takeda M, Ogura T, Makino H. Novel action of activin and bone morphogenetic protein in regulating aldosterone production by human adrenocortical cells. Endocrinology 2004; 145: 639 - 649.
30. Cejalvo T, Sacedón R, Hernández-López C, Diez B, Gutierrez-Frías C, Valencia J, et al. Bone morphogenetic protein-2/4 signaling pathway components are expressed in the human thymus and inhibit early T-cell development. Immunology 2007; 121: 94 - 104.
31. Tsai PT, Lee RA, Wu H. BMP4 acts upetream of FGF in modulating thymic stroma and regulating thymopoiesis. Blood 2003; 102: 3947 - 3953.
32. Bleul CC, Boehm T. BMP signaling is required for normal thymus development. J Immunol 2005; 175: 5213 - 5221.
33. Roberts KE, Barst RJ, McElroy JJ, Widlitz A, Chada K, Knowles JA, et al. Bone morphogenetic protein receptor 2 mutation in adults and children with idiopathic pulmonary arterial hypertension: Association with thyroid disease. Chest 2005; 128: 618S.
34. Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007; 116: 1725 - 1735.